Compare · INM vs JAZZ
INM vs JAZZ
Side-by-side comparison of InMed Pharmaceuticals Inc. (INM) and Jazz Pharmaceuticals plc (JAZZ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INM and JAZZ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JAZZ is the larger of the two at $15.45B, about 1808.2x INM ($8.5M).
- JAZZ has been more active in the news (14 items in the past 4 weeks vs 12 for INM).
- JAZZ has more recent analyst coverage (25 ratings vs 1 for INM).
- Company
- InMed Pharmaceuticals Inc.
- Jazz Pharmaceuticals plc
- Price
- -
- -
- Market cap
- $8.5M
- $15.45B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- News (4w)
- 12
- 14
- Recent ratings
- 1
- 25
InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP-150 for treatment of post-traumatic stress disorder. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.
Latest INM
- InMed Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Financial Statements and Exhibits, Results of Operations and Financial Condition, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status
- Large owner Adar1 Capital Management, Llc bought $34,572 worth of shares (2,640 units at $13.10) (SEC Form 4)
- InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics
- InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- InMed Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
- InMed Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by InMed Pharmaceuticals Inc.
- SEC Form 425 filed by InMed Pharmaceuticals Inc.
- SEC Form 424B3 filed by InMed Pharmaceuticals Inc.
Latest JAZZ
- Brain Cancer Biotech Race Heats Up as NeOnc, Nuvation, Jazz and Cerenome Present New Data at SNO
- Director Cozadd Bruce C exercised 86,500 units of Ordinary Shares at a strike of $136.18 and sold $16,235,517 worth of Ordinary Shares (68,808 units at $235.95), increasing direct ownership by 5% to 357,567 units (SEC Form 4) to cover withholding tax
- SVP, Chief Accounting Officer Carr Patricia exercised 1,250 units of Ordinary Shares at a strike of $140.03 and sold $326,910 worth of Ordinary Shares (1,413 units at $231.36), decreasing direct ownership by 2% to 6,512 units (SEC Form 4)
- SEC Form 144 filed by Jazz Pharmaceuticals plc
- SEC Form 4 filed by Jazz Pharmaceuticals plc
- Amendment: SEC Form SCHEDULE 13G/A filed by Jazz Pharmaceuticals plc
- Director Cozadd Bruce C sold $1,295,040 worth of Ordinary Shares (6,000 units at $215.84) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 339,875 units (SEC Form 4)
- Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
- SEC Form 144 filed by Jazz Pharmaceuticals plc
- SEC Form 10-Q filed by Jazz Pharmaceuticals plc